Baxter International | BAX - Equity Capital And Reserves


Baxter International reported $6.21B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
AngioDynamics USD 176.33M 2.52M Sep/2025
Artivion USD 450.47M 2.24M Mar/2026
AtriCure USD 516.43M 24.74M Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Boston Scientific USD 24.93B 934M Jun/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Dexcom USD 2.62B 335.5M Jun/2026
Edwards Lifesciences USD 10.62B 290.5M Jun/2026
Fresenius EUR 19.7B 766M Jun/2026
Globus Medical USD 4.77B 36.29M Jun/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
ICU Medical USD 2.15B 39.92M Jun/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.42B 119.6M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intuitive Surgical USD 18.17B 693.9M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Medtronic USD 48.99B 128M Dec/2025
Merit Medical Systems USD 1.68B 53.08M Jun/2026
Quest Diagnostics USD 7.52B 150M Jun/2026
Smith & Nephew USD 5.18B 356M Jun/2026
Stryker USD 22.98B 559M Mar/2026
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 2.9B 179.9M Jun/2026
Terumo JPY 1.58T 62.18B Mar/2026
Zimmer Biomet Holdings USD 12.63B 49.1M Jun/2026